USANew treatments and approvals
Rebisufligene etisparvovec receives FDA approval as first treatment for Sanfilippo type A
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA has approved rebisufligene etisparvovec for children with Sanfilippo syndrome type A (MPS IIIA). The drug is meant to treat the nervous system symptoms of the disease. It is used in children whose neurological development is still preserved. This gene therapy is given once, into a vein. It carries the gene for the missing sulfamidase enzyme into the body. It is the first treatment approved in the USA for Sanfilippo type A.
What does it mean for patients and families?
It is important to start treatment early, before the disease progresses. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
GlobeNewswire (Ultragenyx) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Sanfilippo syndrome type A (MPS IIIA)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.